Ángel Eduardo Lobo-Rojas

Prof. Ángel Eduardo Lobo-Rojas

University of Los Andes, Mérida, Venezuela
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Parasitology International
Verified
Journal Article
Closed access
ÁLÁngel Eduardo Lobo-Rojas
Ángel Eduardo Lobo-Rojas
EGEglys B. González-Marcano
Eglys B. González-Marcano
EVEdward A. Valera-Vera
Edward A. Valera-Vera
HAHéctor R. Acosta
Héctor R. Acosta
WQWilfredo A Quiñones
Wilfredo A Quiñones
ACAna J. Cáceres
Ana J. Cáceres

13 December 2024 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JFJessica Do Nascimento Faria
Jessica Do Nascimento Faria
AEAmanda G. Eufrásio
Amanda G. Eufrásio
MFMichelle Fagundes
Michelle Fagundes
ÁLÁngel Eduardo Lobo-Rojas
Ángel Eduardo Lobo-Rojas
LMLetícia Marchese
Letícia Marchese
ACArtur Cordeiro
Artur Cordeiro
Trypanosoma cruzi is a flagellated protozoan and the etiological agent of Chagas disease, a neglected tropical disease described by Carlos Chagas in 1909 that remains without appropriate diagnostics and treatment. Throughout its life cycle, T. cruzi undergoes through many different environments, requiring adaptation of its metabolism to different nutrition sources. Recent studies have confirmed the adaptability of T. cruzi metabolism to different carbon sources and encouraged a deeper investigation of related metabolic pathways. In the present study, we investigated the catabolism of threonine in T. cruzi epimastigotes cultivated in LIT medium and following 24h of starvation in PBS. In LIT medium, threonine, serine, and histidine were rapidly consumed concomitantly with carbohydrates during parasite exponential growth. When threonine was provided as the only carbon source to starved parasites, they excreted acetate and glycine, corroborating the activity of a mitochondrial threonine degradation pathway. Subsequently, we used a recombinant T. cruzi L-threonine dehydrogrenase (TcTDH) to screen the Chagas Box, an open-source collection of phenotypic hits, and identified compound TCMDC-143160 as a low micromolar TcTDH inhibitor (IC50 = 3.5 μM). When TCMDC-143160 was administrated to starved parasites, it inhibited the threonine degradation pathway. Finally, we report the crystal structure of TcTDH and characterize its allosteric activation by potassium. Collectively, these data demonstrate the relevance of threonine catabolism in T. cruzi metabolism and provide a set of tools to further investigate TcTDH as a potential drug target for Chagas disease.

11 October 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
ÁLÁngel Eduardo Lobo-Rojas
Ángel Eduardo Lobo-Rojas
EQEnder Javier Quintero-Troconis
Ender Javier Quintero-Troconis
RRRocío Del Valle Rondón
Rocío Del Valle Rondón
MPMary Carmen Perez
Mary Carmen Perez
JCJuan Luis Concepción
Juan Luis Concepción
ACAna Judith Cáceres
Ana Judith Cáceres
In this study, we demonstrate that Trypanosoma cruzi epimastigotes previously grown in LIT medium supplemented with 20 mM galactose and exposed to sub-lethal concentrations of hydrogen peroxide (100 μM) showed two-fold and five-fold viability when compared to epimastigotes grown in LIT medium supplemented with two different glucose concentrations (20 mM and 1.5 mM), respectively. Similar results were obtained when exposing epimastigotes from all treatments to methylene blue 30 μM. Additionally, through differential centrifugation and the selective permeabilization of cellular membranes with digitonin, we found that phosphoglucomutase activity (a key enzyme in galactose metabolism) occurs predominantly within the cytosolic compartment. Furthermore, after partially permeabilizing epimastigotes with digitonin (0.025 mg × mg−1 of protein), intact glycosomes treated with 20 mM galactose released a higher hexose phosphate concentration to the cytosol in the form of glucose-1-phosphate, when compared to intact glycosomes treated with 20 mM glucose, which predominantly released glucose-6-phosphate. These results shine a light on T. cruzi’s galactose metabolism and its interplay with mechanisms that enable resistance to oxidative stress.

1 May 2018 in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Verified
Journal Article
Closed access
EQE. Quintero-Troconis
E. Quintero-Troconis
NBN. Buelvas
N. Buelvas
César Carrasco-LópezCésar Carrasco-López
César Carrasco-López
MDM.R. Domingo-Sananes
M.R. Domingo-Sananes
LGL. González-González
L. González-González
JCJ.L. Concepción
J.L. Concepción

4 March 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
ÁLÁngel Eduardo Lobo-Rojas
Ángel Eduardo Lobo-Rojas
LMLetícia Marchese
Letícia Marchese
AEAmanda G. Eufrasio
Amanda G. Eufrasio
GSGabriel T. D. Souza
Gabriel T. D. Souza
MCMichelle F. Catelli
Michelle F. Catelli
ACArtur Cordeiro
Artur Cordeiro
Chagas disease, caused by Trypanosoma cruzi , remains a leading cause of heart failure in Latin America, with current treatments limited to acute-phase efficacy, significant toxicity, and emerging resistance. Inosine monophosphate dehydrogenase (IMPDH) is an essential enzyme in guanine nucleotide salvage pathway and represents a promising alternative target. Here, we combined computational screening, biochemical and cell-based phenotypic assays that support T. cruzi IMPDH ( Tc IMPDH) as a druggable target and identify repurposing opportunities among clinical-stage inhibitors. Using Tanimoto similarity scoring against the library of 222 Chagas Box compounds, we identified TCMDC-143376 as uniquely similar to the clinical IMPDH inhibitors merimepodib and AVN-944. Phylogenetic analysis and multiple sequence alignment confirmed conservation of both catalytic and allosteric residues—drawn from T. foetus and T. brucei structures—within Tc IMPDH. Recombinant Tc IMPDH kinetics revealed Michaelis constants of 155 µM for IMP and 292 µM for NAD + . Biochemical IC 50 assays showed submicromolar inhibition by AVN-944 (0.20 µM), (S)-Merimepodib (0.21 µM), and (R)-Merimepodib (0.37 µM). In H9c2 cardiomyoblasts infected with intracellular amastigotes, AVN-944 achieved the lowest EC 50 (0.4 µM), outperforming benznidazole (EC 50 = 3.0 µM) and other inhibitors. Our findings support Tc IMPDH as a promising alternative drug target for Chagas disease and position AVN-944 as a compelling candidate to evaluate this therapeutic strategy in animal models.

7 August 2025 in bioRxiv
Verified
Preprint
Open access
ÁLÁngel Eduardo Lobo-Rojas
Ángel Eduardo Lobo-Rojas
MLMarchese Letícia
Marchese Letícia
GAG. Eufrásio Amanda
G. Eufrásio Amanda
DGD. T. Souza Gabriel
D. T. Souza Gabriel
FMF. Catelli Michelle
F. Catelli Michelle
ACArtur Cordeiro
Artur Cordeiro
Chagas disease, caused by Trypanosoma cruzi , remains a leading cause of heart failure in Latin America, with current treatments limited to acute-phase efficacy, significant toxicity, and emerging resistance. Inosine monophosphate dehydrogenase (IMPDH) is an essential enzyme in guanine nucleotide salvage pathway and represents a promising alternative target. Here, we combined computational screening, biochemical and cell-based phenotypic assays that support T. cruzi IMPDH ( Tc IMPDH) as a druggable target and identify repurposing opportunities among clinical-stage inhibitors. Using Tanimoto similarity scoring against the library of 222 Chagas Box compounds, we identified TCMDC-143376 as uniquely similar to the clinical IMPDH inhibitors Merimepodib and AVN-944. Phylogenetic analysis and multiple sequence alignment confirmed conservation of both catalytic and allosteric residues—drawn from T. foetus and T. brucei structures—within Tc IMPDH. Recombinant Tc IMPDH kinetics revealed Michaelis constants of 155 µM for IMP and 292 µM for NAD⁺. Biochemical IC₅ ₀ assays showed submicromolar inhibition by AVN-944 (0.20 µM), (S)-Merimepodib (0.21 µM), and (R)-Merimepodib (0.37 µM). In H9c2 cardiomyoblasts infected with intracellular amastigotes, AVN-944 achieved the lowest EC₅ ₀ (0.4 µM) and highest selectivity index (SI > 100), outperforming benznidazole (EC₅ ₀ = 3.0 µM; SI = 13.4) and other inhibitors. Our findings support Tc IMPDH as a promising alternative drug target for Chagas disease and position AVN-944 as a compelling candidate to evaluate this therapeutic strategy in animal models.